McCarthy Asset Management’s Novavax NVAX Stock Holding History

McCarthy Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-116	Closed	-$9K	–	200
2022 Q1	$9K	Buy	116 +70	+152%	+$6.24K	0.01%	173
2021 Q4	$7K	Buy	+46	New	+$7.9K	﹤0.01%	180

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

McCarthy Asset Management's NVAX Position: Q2 2022 in Review

McCarthy Asset Management sold out of Novavax (NVAX) in Q2 2022, closing a stake of 116 shares — an estimated $9K sold.

McCarthy Asset Management first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $9K in Q1 2022. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

McCarthy Asset Management reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
McCarthy Asset Management sold 116 Novavax shares in Q2 2022, an estimated $9K.
McCarthy Asset Management first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
McCarthy Asset Management's Novavax position peaked at $9K in Q1 2022.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.